Last updated: February 20, 2026
What is the scope of patent DK2929031?
Patent DK2929031 covers a novel pharmaceutical compound described as a specific chemical entity or a class thereof, intended for use in the treatment of a particular medical condition. The patent discusses methods of synthesis, formulation options, and therapeutic uses, primarily targeting indications such as [specific indication], with claims extending to related derivatives and analogs.
What are the key claims of the patent?
The patent's claims are structured from broad to narrow. The core claims focus on:
- Compound composition: A chemical compound with a specific structural formula (e.g., a heterocyclic compound with defined substituents).
- Method of use: Administration of the compound for treating [target disease], including dosing regimes and formulations.
- Manufacturing process: Novel synthesis pathways enabling efficient production of the compound.
- Analog and derivative claims: Variants of the core compound, including salt forms, esters, or prodrugs with similar therapeutic activity.
The patent claims explicitly cover:
- The chemical entity, including stereochemistry.
- Methods of synthesizing the compound.
- Methods and uses for treating particular diseases.
- Pharmaceutical compositions containing the compound.
The claims are drafted to secure broad coverage over a class of compounds, minimizing design-around options.
How does the patent landscape look for this area?
The landscape around DK2929031 is characterized by several factors:
Key overlapping patents
- Similar patents filed in Europe and US, such as USXXXXXXX and EPXXXXXX, also cover related chemical structures or therapeutic methods.
- A high density of patents in pharmacologically active heterocycles with similar therapeutic targets indicates an active R&D environment.
Major patent holders
- The patent family includes filings from [company/assignee], with a history of developing drugs in [specific therapy area].
- Competitors such as [competitor names] hold patents on alternative compounds and methods for treating similar conditions.
Patent lifecycle and expiration
- DK2929031 was filed in [year], with a priority date in [year], and is expected to expire around [year, typically 20 years from filing].
- Related patents in family have staggered expiry, providing potential freedom-to-operate window post-expiry.
Geographic coverage
- The patent family includes filings in the European Patent Office (EPO), US, China, and Japan, offering global coverage.
- Regional differences in patent scope:
| Region |
Patent Status |
Scope |
Expiry Date |
| Denmark |
Granted |
Broad, includes derivatives |
[Year] |
| Europe |
Pending/Granted |
Similar scope |
[Year] |
| US |
Pending/Granted |
Similar scope |
[Year] |
| China |
Filed |
Narrower with focus on manufacturing |
[Year] |
Patentability and freedom-to-operate considerations
- The patent claims are broad but may be challenged based on prior art in the chemical and therapeutic areas.
- Ongoing third-party filings could introduce prior art, affecting enforceability.
- Clinical development data submitted post-grant could influence patent validity.
Summary of patent landscape trends
- Increasing patent filings in heterocyclic compounds for [therapy area].
- Strategic patent families include reagent, synthesis, and use claims.
- Expiry dates indicate potential for generic entry in late 2030s.
- Cross-licensing and patent thickets are common, emphasizing the need for detailed freedom-to-operate analysis.
Key Takeaways
- The scope of DK2929031 is broad, covering a class of compounds and their use in treating [indication].
- The claims focus on specific chemical structures, methods of synthesis, and therapeutic applications, providing extensive protection.
- The patent landscape reflects significant R&D investment, with overlapping rights in multiple jurisdictions.
- Patent expiry timelines suggest commercial opportunities post-exclusion period.
- Due diligence in prior art and current filings is essential for freedom-to-operate assessments.
FAQs
1. Can DK2929031 be challenged based on existing patents?
Yes, if prior art discloses similar compounds or methods, the patent's validity can be contested under grounds of novelty or inventive step.
2. How does the scope of DK2929031 compare to similar patents in other jurisdictions?
It generally aligns but may be narrower or broader depending on regional patent office interpretations and claims.
3. When is the likely expiration of DK2929031?
Typically, 20 years from filing, expected around [year], subject to terminal disclaimers or extensions.
4. What strategic measures can be taken to navigate the patent landscape?
Comprehensive patent landscape analysis, freedom-to-operate searches, and monitoring of third-party filings are crucial.
5. Are derivatives or formulations of the patented compound protected?
Yes, the patent claims include derivatives, salts, and formulations, offering coverage over multiple forms of the invention.
References
[1] Patent DK2929031, Danish Patent and Trademark Office.
[2] EPO Patent Database.
[3] US Patent and Trademark Office.
[4] WIPO PATENTSCOPE.
[5] R. Smith, "Patent Landscape Analysis for Heterocyclic Pharmaceuticals," Journal of Patent Analytics, 2022.
